Corrigendum to “Development of dextrin-amphotericin B formulations for the treatment of Leishmaniasis” [Int. J. Biol. Macromol., 15 (2020) 276–288](S0141813019404066)(10.1016/j.ijbiomac.2020.03.019)

Abstract

The authors regret to inform that there are some inaccuracies in the above referred article. More specifically, in the end of the Results and Discussion section 3.6. Anti-Leishmania activity against axenic promastigote and intramacrophagic L. infantum amastigotes it is described the following “Dex-AmB nanocomplexes had an activity similar to the free-drug, despite the slightly higher IC50 values - 0.017 ± 0.009 and 0.023 ± 0.006 μM for Dex-AmB FD and Dex-AmB SD, respectively - promoting a decrease in the amastigote parasite burden in the used concentration range. These results are consistent with the literature where reduced and unreduced AmB-AG conjugates were able to decrease the percentage of macrophages infected with L. infantum (ED50 of 0.035 mg/mL and 0.027 mg/mL, respectively) [75]”. In this sentence the units “mg/mL” are incorrect and the correct ones are “μg/mL”. Moreover, the reference numbered with 75 should be “J. Golenser, et al., Efficacious treatment of experimental leishmaniasis with amphotericin B-arabinogalactan water-soluble derivatives. Antimicrob Agents Chemother 43(9) (1999) 2209-14” instead of “R. Falk, et al. A novel injectable water-soluble amphotericin B-arabinogalactan conjugate. Antimicrob. Agents Chemother., 43 (8) (1999), pp. 1975-1981”. The authors would like to apologise for any inconvenience caused.